Eric S. Lightcap

Eric S. Lightcap

Auto-generated profile, based on publicly available information

Eric S. Lightcap

HiberCell, Inc., Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
ELEric S. Lightcap
Eric S. Lightcap
PYPengfei Yu
Pengfei Yu
SGStephen Grossman
Stephen Grossman
KSKeli Song
Keli Song
MKMithun Khattar
Mithun Khattar
DHDennis Huszar
Dennis Huszar
TAK-981, a first-in-class small-molecule SUMOylation inhibitor, activates type I interferon signaling to promote antitumor immune responses in mice.

1 June 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KGKhristofer Garcia
Khristofer Garcia
JBJonathan L. Blank
Jonathan L. Blank
DBDavid C. Bouck
David C. Bouck
XLXiaozhen J. Liu
Xiaozhen J. Liu
DSDarshan S. Sappal
Darshan S. Sappal
ELEric S. Lightcap
Eric S. Lightcap
MLN4924 is an investigational small-molecule inhibitor of the Nedd8-activating enzyme currently in phase I clinical trials. MLN4924 induces DNA damage via rereplication in most cell lines. This distinct mechanism of DNA damage may affect its ability to combine with standard-of-care agents and may affect the clinical development of MLN4924. As such, we studied its interaction with other DNA-damaging agents. Mitomycin C, cisplatin, cytarabine, UV radiation, SN-38, and gemcitabine demonstrated synergy in combination with MLN4924 in vitro. The combination of mitomycin C and MLN4924 was shown to be synergistic in a mouse xenograft model. Importantly, depletion of genes within the ataxia telangiectasia and Rad3 related (ATR) and BRCA1/BRCA2 pathways, chromatin modification, and transcription-coupled repair reduced the synergy between mitomycin C and MLN4924. In addition, comet assay demonstrated increased DNA strand breaks with the combination of MLN4924 and mitomycin C. Our data suggest that mitomycin C causes stalled replication forks, which when combined with rereplication induced by MLN4924 results in frequent replication fork collisions, leading to cell death. This study provides a straightforward approach to understand the mechanism of synergy, which may provide useful information for the clinical development of these combinations. Mol Cancer Ther; 13(6); 1625–35. ©2014 AACR.

21 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MSMichael E Stokes
Michael E Stokes
VCVeronica Calvo
Veronica Calvo
SFSho Fujisawa
Sho Fujisawa
CDCrissy Dudgeon
Crissy Dudgeon
SHSharon Huang
Sharon Huang
DSDavid Surguladze
David Surguladze
Purpose: Tumors activate protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK, also called EIF2AK3) in response to hypoxia and nutrient deprivation as a stress-mitigation strategy. Here, we tested the hypothesis that inhibiting PERK with HC-5404 enhances the antitumor efficacy of standard-of-care VEGF receptor tyrosine kinase inhibitors (VEGFR-TKI). Experimental Design: HC-5404 was characterized as a potent and selective PERK inhibitor, with favorable in vivo properties. Multiple renal cell carcinoma (RCC) tumor models were then cotreated with both HC-5404 and VEGFR-TKI in vivo, measuring tumor volume across time and evaluating tumor response by protein analysis and IHC. Results: VEGFR-TKI including axitinib, cabozantinib, lenvatinib, and sunitinib induce PERK activation in 786-O RCC xenografts. Cotreatment with HC-5404 inhibited PERK in tumors and significantly increased antitumor effects of VEGFR-TKI across multiple RCC models, resulting in tumor stasis or regression. Analysis of tumor sections revealed that HC-5404 enhanced the antiangiogenic effects of axitinib and lenvatinib by inhibiting both new vasculature and mature tumor blood vessels. Xenografts that progress on axitinib monotherapy remain sensitive to the combination treatment, resulting in ∼20% tumor regression in the combination group. When tested across a panel of 18 RCC patient-derived xenograft (PDX) models, the combination induced greater antitumor effects relative to monotherapies. In this single animal study, nine out of 18 models responded with ≥50% tumor regression from baseline in the combination group. Conclusions: By disrupting an adaptive stress response evoked by VEGFR-TKI, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard-of-care therapies in RCC.

18 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMTomoko Yamamori Morita
Tomoko Yamamori Morita
JYJie Yu
Jie Yu
YKYukie Kashima
Yukie Kashima
RKRyo Kamata
Ryo Kamata
GYGaku Yamamoto
Gaku Yamamoto
AOAkihiro Ohashi
Akihiro Ohashi
Serine/threonine kinase, cell division cycle 7 (CDC7) is critical for initiating DNA replication. TAK-931 is a specific CDC7 inhibitor, which is a next-generation replication stress (RS) inducer. This study preclinically investigates TAK-931 antitumor efficacy and immunity regulation. TAK-931 induce RS, generating senescence-like aneuploid cells, which highly expressed inflammatory cytokines and chemokines (senescence-associated secretory phenotype, SASP). In vivo multilayer-omics analyses in gene expression panel, immune panel, immunohistochemistry, RNA sequencing, and single-cell RNA sequencing reveal that the RS-mediated aneuploid cells generated by TAK-931 intensively activate inflammatory-related and senescence-associated pathways, resulting in accumulation of tumor-infiltrating immune cells and potent antitumor immunity and efficacy. Finally, the combination of TAK-931 and immune checkpoint inhibitors profoundly enhance antiproliferative activities. These findings suggest that TAK-931 has therapeutic antitumor properties and improved clinical benefits in combination with conventional immunotherapy.

26 March 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CTChristopher G. Thomson
Christopher G. Thomson
TAThomas D. Aicher
Thomas D. Aicher
WCWeiwei Cheng
Weiwei Cheng
HDHongwen Du
Hongwen Du
CDCrissy Dudgeon
Crissy Dudgeon
SRSavithri Ramurthy
Savithri Ramurthy

20 August 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
FTFeven Tameire
Feven Tameire
PWPaulina Wojnarowicz
Paulina Wojnarowicz
CDCrissy Dudgeon
Crissy Dudgeon
KBKathryn T. Bieging-Rolett
Kathryn T. Bieging-Rolett
SFSho Fujisawa
Sho Fujisawa
ELEric S. Lightcap
Eric S. Lightcap
General control nonderepressible 2 (GCN2; EIF2AK4) is a serine–threonine kinase in the integrated stress response signaling pathway that initiates adaptive responses during nutrient stress conditions. Although pharmacologic inhibition of GCN2 under nutrient stress conditions induces apoptosis and inhibits tumor growth, GCN2 inhibition without nutrient stress has been reported to have no effect on tumor growth. By exploring an array of GCN2 inhibitors, we demonstrate that multiple agents in fact activate GCN2 in biochemical and cell-based assays at low concentrations and inhibit GCN2 at higher concentrations. Unexpectedly, it is this activation, and not inhibition, of the GCN2 pathway that is associated with decreased viability in vitro and tumor growth inhibition in vivo across multiple models. Knockdown and knockout experiments show that activation of the integrated stress response by GCN2-targeting agents is dependent on GCN2. ISRIB, a modulator of eIF2B, ablates the viability effect, demonstrating the dependence on translation initiation. Activating doses result in the induction of cleaved caspase 3 and cleaved PARP. In contrast, a nonactivating GCN2-targeting agent does not affect viability. These results provide a clearer understanding of the challenges and opportunities for the clinical development of compounds targeting GCN2.